Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4649-4667
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4649
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4649
Figure 1 Anoctamin 5 expression in gastric cancer cells.
A: Real-time quantitative reverse transcription-quantitative polymerase chain reaction (PCR) showed the expression of anoctamin 5 (ANO5) in various cell lines in gastric cancer; B: Western blotting showed the expression of ANO5 in various cell lines in GC; C: Real-time quantitative PCR revealed that ANO5 small interfering RNA (siRNA) effectively reduced ANO5 mRNA levels in NUGC4 and MKN45 cells; D: Western blotting revealed that ANO5 siRNA effectively reduced ANO5 protein levels in NUGC4 and MKN45 cells. n = 3, mean ± standard error of the mean. aP < 0.05 (significantly different from control siRNA). ANO5: Anoctamin 5; ACTB: β-actin; siRNA: Small interfering RNA.
- Citation: Fukami T, Shiozaki A, Kosuga T, Kudou M, Shimizu H, Ohashi T, Arita T, Konishi H, Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Morinaga Y, Konishi E, Otsuji E. Anoctamin 5 regulates the cell cycle and affects prognosis in gastric cancer. World J Gastroenterol 2022; 28(32): 4649-4667
- URL: https://www.wjgnet.com/1007-9327/full/v28/i32/4649.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i32.4649